Skip to content
Screener

PP&E (Net) at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$23.58B+7.4%
Amgen logo
AmgenAMGN
$8.55B+24.7%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$1.28M-26.5%
Vor Biopharma logo
Vor BiopharmaVOR
$565K-90.6%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$263K-53.8%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$5.35M-39.7%

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$6.15B+838%
Enterprise value$5.52B+758%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0.0×
Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001690585-26-000022
Line itemMarch 31,2026December 31,2025
Prepaid expenses and other current assets7,4225,091
Total current assets1,119,911409,438
Long-term investments113,868110,135
Property and equipment, net274296
Right-of-use operating lease assets1,2931,337
Other assets and restricted cash11,5389,716
Total assets$1,246,884$530,922
Liabilities and Stockholders’ Equity

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Dianthus Therapeutics's PP&E (net)?
Dianthus Therapeutics (DNTH) reported PP&E (net) of $274K in Q1 2026.
How has Dianthus Therapeutics's PP&E (net) changed year-over-year?
Dianthus Therapeutics's PP&E (net) increased by 43.5% year-over-year, from $191K to $274K.
What is the long-term trend for Dianthus Therapeutics's PP&E (net)?
Over 5 years (2020 to 2025), Dianthus Therapeutics's PP&E (net) has grown at a -48.7% compound annual growth rate (CAGR), from $8.31M to $296K.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.

Ask your AI about Dianthus Therapeutics's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude